Kilitch Drugs (India) is currently trading at Rs. 121.15, up by 7.85 points or 6.93% from its previous closing of Rs. 113.30 on the BSE.
The scrip opened at Rs. 119.95 and has touched a high and low of Rs. 125.00 and Rs. 119.95 respectively. So far 4574 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 134.90 on 28-Feb-2018 and a 52 week low of Rs. 48.55 on 22-Aug-2017.
Last one week high and low of the scrip stood at Rs. 125.00 and Rs. 106.20 respectively. The current market cap of the company is Rs. 155.58 crore.
The promoters holding in the company stood at 65.79%, while Non-Institutions held at 34.21%.
Kilitch Drugs (India) (KDIL) has planned to focus on African markets with a state-of-the-art Cephalosporin injectable plant near Adis Ababa - capital city of Ethiopia. The unit will have a capacity of 20 million vials and commence operations in FY19-20. Besides vials, the plant will also produce tablets, capsules, dry syrup, etc.
By 2020, KDIL plans to register more than 500 products in the African markets, which is the next bastion for growth.
Kilitch Drugs (India) is an India-based company engaged in pharmaceutical business. The Company’s services range from manufacturing to marketing a host of formulations in all dosage forms, such as solid, liquid and parenteral forms.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: